𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Strategies to alter the progression of Alzheimer's disease

✍ Scribed by Robert Siman; Richard W. Scott

Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
670 KB
Volume
7
Category
Article
ISSN
0958-1669

No coin nor oath required. For personal study only.

✦ Synopsis

Recent advances in the genetics of familial Alzheimer's disease provide direction for therapeutic strategies to alter the progressive neurodegeneration. The rationale is particularly strong for targeting the deposition of amyloid into neuritic plaques, but attention has also turned to abnormalities in apoptosis and signal-transduction processes.

πŸ“œ SIMILAR VOLUMES

Hippocampal Subregions are Differentiall
Hippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease
✍ Sarah J. Greene; Ronald J. Killiany; The Alzheimer's Disease Neuroimaging Initia πŸ“‚ Article πŸ“… 2011 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 331 KB πŸ‘ 2 views

## Abstract Atrophy within the hippocampus (HP) as measured by magnetic resonance imaging (MRI) is a promising biomarker for the progression to Alzheimer's disease (AD). Subregions of the HP along the longitudinal axis have been found to demonstrate unique function, as well as undergo differential

Progression in alzheimer's disease: Sequ
Progression in alzheimer's disease: Sequencing of neuropsychological decline
✍ Ove Almkvist; Lars BΓ€ckman πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 747 KB

## Abstract The progression of cognitive and motor functions in Alzheimer's disease (AD) patients and healthy aged individuals was studied. For the healthy aged, the progress was negligible during a 2‐year period. In the AD patients, there was a marked progression in all cognitive tests, but only a

Measurement of progression in Alzheimer'
Measurement of progression in Alzheimer's disease: a clinician's perspective
✍ Douglas J. Gelb πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 62 KB πŸ‘ 2 views

Patients with Alzheimer's disease (AD) and their families must confront two fundamental truths. First, AD is a uniformly progressive disease that ultimately results in debilitating cognitive impairment. Second, although there is now evidence that some medications may produce transient improvement or